CervoMed Inc.
CRVO · Nasdaq · United States
Share price · CRVO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CRVO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026+29.2%
Nothing announced by CRVO that day or the session before.
- 29 Oct 2026-20.8%
- 12 Oct 2026-22.0%
- 5 Oct 2026+9.6%
Nothing announced by CRVO that day or the session before.
- 29 Sep 2026+7.9%
- 16 Jun 2026+82.3%
- Day beforeRegulation FD disclosure
- 10 Jun 2026-22.1%
- 20 May 2026+12.1%
Nothing announced by CRVO that day or the session before.
- 18 May 2026-11.6%
- 20 Feb 2026-11.5%
Nothing announced by CRVO that day or the session before.
Share of unusual movement by asset
For each asset, the share of CRVO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | p38-alpha MAPKSmall molecule | Dementia with Lewy Bodies |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $3.7M | $6.1M+ $14M short-term inv. | $5.9M-$5.1M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $4.3M | $22M+ $2.5M short-term inv. | $6.6M-$6.9M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $5.1M | —+ $5.0M short-term inv. | $8.0M-$8.0M operating cash flow | report ↗ |
| 2025-Q3 | $0.3M | $6.0M | —+ $18M short-term inv. | $7.7M-$6.5M operating cash flow | report ↗ |
| 2025-Q2 | $1.8M | $5.1M | —+ $25M short-term inv. | $6.3M-$6.5M operating cash flow | report ↗ |
| 2025-Q1 | $1.9M | $4.8M | $11M+ $25M short-term inv. | $4.9M-$3.9M operating cash flow | report ↗ |
| 2024-Q3 | $1.9M | $5.1M | $7.7M+ $39M short-term inv. | $4.8M-$4.8M operating cash flow | report ↗ |
| 2024-Q2 | $3.3M | $3.8M | $10M+ $35M short-term inv. | $2.3M-$2.2M operating cash flow | report ↗ |
| 2024-Q1 | $2.4M | $2.8M | $6.4M | $2.5M-$1.4M operating cash flow | report ↗ |
| 2023-Q3 | $1.5M | $1.8M | $10M | —$2.7M operating cash flow | report ↗ |
| 2023-Q2 | $1.7M | $0.1M | $15M+ $0 short-term inv. | $2.1M-$2.6M operating cash flow | report ↗ |
| 2023-Q1 | $1.4M | $1.3M | $15M+ $3.0M short-term inv. | $4.1M-$5.0M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $0.8M | $4.8M+ $19M short-term inv. | $2.8M-$2.8M operating cash flow | report ↗ |
| 2022-Q2 | — | $2.1M | $6.0M+ $23M short-term inv. | $4.2M-$4.0M operating cash flow | report ↗ |
| 2022-Q1 | — | $2.4M | $9.9M+ $23M short-term inv. | $4.5M-$4.7M operating cash flow | report ↗ |
| 2021-Q3 | — | $2.1M | $40M | $12M-$3.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $4.0M | $22M | —+ $13M short-term inv. | $6.7M-$23M operating cash flow | report ↗ |
CervoMed reported FY 2025 revenue of $4.01M, down 58.8% YoY, and R&D spend of $21.82M, up 16.1% YoY. Cash and equivalents were not disclosed. The company recorded a net loss of $26.97M and a quarterly net burn of $26.97M.
The filing centers on neflamapimod for dementia with Lewy bodies (DLB), non-fluent variant primary progressive aphasia (nfvPPA), recovery after stroke (RAS), and ALS. Management reported 16-week and 32-week extension results from the RewinD-LB trial and FDA alignment on key aspects of a planned Phase 3 DLB trial, which is expected to initiate in 2H26 subject to funding. For the Phase 2a trials initiated in 2025, enrollment completion is expected in 2Q26 for nfvPPA and mid-2026 for RAS, with initial nfvPPA biomarker data in mid-2026, topline RAS data in 2H26, initial nfvPPA clinical data in 2H26, topline nfvPPA data in 1H27, and first patient dosing in the EXPERTS-ALS trial expected at YE26.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $9.7M | $19M | $9.0M+ $30M short-term inv. | $4.1M-$17M operating cash flow | report ↗ |
| 2023-FY | $7.1M | $8.4M | $7.8M+ $0 short-term inv. | $0.5M-$7.5M operating cash flow | report ↗ |
| 2022-FY | $0 | $7.2M | $10M+ $12M short-term inv. | $3.9M-$15M operating cash flow | report ↗ |
| 2021-FY | — | $8.5M | $37M+ $0 short-term inv. | $6.0M-$15M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($3.2M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-18 | ALAM JOHN J · director, CEO & President, 10% owner | Open-market purchase | 23,681 | $1.51 | $36K | Form 4 |
| 2026-11-18 | ALAM JOHN J · director, CEO & President, 10% owner | Open-market purchase | 76,319 | $1.53 | $117K | Form 4 |
| 2026-10-22 | Winton Matthew · Chief Commercial and Business | Award / grant (derivative) | 19,100 | — | — | Form 4 |
| 2026-10-22 | De Rosch Mark · EVP, RA and GA and PgM | Award / grant (derivative) | 19,100 | — | — | Form 4 |
| 2026-10-22 | Blackburn Kelly · EVP, Clinical Development | Award / grant (derivative) | 19,100 | — | — | Form 4 |
| 2026-06-11 | BOGER JOSHUA S · director, 10% owner | Open-market purchase | 955,414 | $3.14 | $3.0M | Form 4 |
| 2026-06-11 | BOGER JOSHUA S · director, 10% owner | Open-market purchase (derivative) | 955,414 | — | — | Form 4 |
| 2026-06-11 | BOGER JOSHUA S · director, 10% owner | Open-market purchase (derivative) | 955,414 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 36 reporting institutions held 1.8M shares ($7.0M, 11.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | MORGAN STANLEY | 739,892 | $2.9M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 316,202 | $1.2M |
| 3 | MILLENNIUM MANAGEMENT LLC | 208,908 | $823K |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 74,371 | $293K |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 63,904 | $252K |
| 6 | BlackRock, Inc. | 51,660 | $204K |
| 7 | XTX Topco Ltd | 38,487 | $152K |
| 8 | CITIZENS FINANCIAL GROUP INC/RI | 37,477 | $148K |
| 9 | VANGUARD FIDUCIARY TRUST CO | 36,151 | $142K |
| 10 | NORTHERN TRUST CORP | 30,044 | $118K |
| 11 | Cetera Investment Advisers | 27,337 | $108K |
| 12 | Savvy Advisors, Inc. | 25,922 | $102K |
| 13 | STATE STREET CORP | 20,527 | $81K |
| 14 | JANE STREET GROUP, LLC | 18,246 | $72K |
| 15 | Russell Investments Group, Ltd. | 16,090 | $63K |